Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Ovarian Neoplasms 2Endometrial Neoplasms 2Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

Bevacizumab 19Paclitaxel 16Carboplatin 12pembrolizumab 11liposomal doxorubicin 10Cyclophosphamide 9Specimen Handling 8Gemcitabine 8olaparib 7fludarabine 7Topotecan 7Magnetic Resonance Spectroscopy 7Taxes 5Immunoglobulin G 5Fulvestrant 5Disulfides 5niraparib 4Oxaliplatin 4Nivolumab 4Biopsy 4trastuzumab deruxtecan 3palbociclib 3mirvetuximab soravtansine 3aldesleukin 3Leucovorin 3Fluorouracil 31-dodecylpyridoxal 3ulixertinib 2nilotinib 2ipatasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × AZD5305 × 30 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡